Q2 Earnings Estimate for RAPT Issued By HC Wainwright

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for RAPT Therapeutics in a report issued on Thursday, May 22nd. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a "Strong-Buy" rating and a $6.00 price target on the stock. The consensus estimate for RAPT Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.

Several other research analysts have also recently commented on RAPT. UBS Group lowered their target price on shares of RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Wall Street Zen upgraded shares of RAPT Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $3.00.

RAPT Therapeutics Trading Down 6.5%

Shares of NASDAQ RAPT traded down $0.06 during mid-day trading on Monday, hitting $0.87. The company had a trading volume of 60,891 shares, compared to its average volume of 1,283,506. The firm has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $1.13. The company has a market capitalization of $115.09 million, a PE ratio of -0.31 and a beta of -0.04. RAPT Therapeutics has a one year low of $0.71 and a one year high of $4.60.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.23.

Institutional Investors Weigh In On RAPT Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RAPT. SG Americas Securities LLC lifted its stake in shares of RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after buying an additional 42,636 shares in the last quarter. Sei Investments Co. bought a new position in shares of RAPT Therapeutics during the 4th quarter valued at $64,000. JPMorgan Chase & Co. grew its holdings in shares of RAPT Therapeutics by 1,128.3% during the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock valued at $324,000 after purchasing an additional 188,461 shares during the last quarter. Renaissance Technologies LLC boosted its position in RAPT Therapeutics by 25.5% during the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock valued at $584,000 after buying an additional 75,136 shares during the period. Finally, Comerica Bank purchased a new stake in RAPT Therapeutics during the 4th quarter valued at $92,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.